The firms entered into a merger agreement in February for Novo Holdings to acquire Catalent in an all-cash transaction worth $16.5 billion. That deal still expects to close toward the end of ...

Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below ...

At the same time, Catalent is one of the “very few” contract drug manufacturers that provides specialized development and manufacturing services to companies that sell these medicines.

Update 12:30pm: Adds Catalent response. The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Holdings to purchase Catalent ...

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a ...